In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

The funding will support the development of Revolution's RAS(ON) inhibitor daraxonrasib in exchange for tiered royalties on its sales.

In a Phase I/II clinical trial, TKI-pretreated NSCLC patients given zidesamtinib had an overall response rate of 44 percent.

UCLA-led investigators say additional research is needed into why guideline-recommended genetic testing remains low among ...

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.

The agency maintains that the beta-amyloid-targeting drugs show too limited benefit to justify their cost to the National Health Service.

The funding comes from the Foundation Fighting Blindness' venture philanthropy arm, the Retinal Degeneration Fund.

The agency granted the accelerated approval for Datroway in EGFR-mutant NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials.

Top-line results from a Phase III trial showed an overall survival benefit for zanzalintinib combo therapy in microsatellite-stable colorectal cancer.

For selected applicants, the agency plans to cut review times down to one to two months and provide "tumor board-style" ...